Anticancer effect of PMEDAP--monitoring of apoptosis.

Abstract

Antitumor effect of N-9-[2-(phosphonomethoxy) ethyl]-2,6-diaminopurine (PMEDAP) was studied in an in vivo model of s.c. transplanted Sprague-Dawley (SD/cub) rat T-cell lymphomas. Three individual SD/cub neoplasias (SD10/96, SD14/97, SD1/90) of different phenotypes were used. During the treatment, survival of the rats, increase of lymphoma mass, and DNA fragmentation detected by APO/BRDU kit, as well as Bcl2 and p53 protein expression, were followed. The study gives evidence of the positive therapeutic effect of PMEDAP in two of the three tested lymphomas, SD10/96 and SD14/97. Slowly growing SD1/90 lymphoma differs from the others in a uniform karyotype with trisomy of chromosome 11, CD4- immunophenotype, heterogeneous cellular morphology and constitutive expression of p53 protein found in some neoplastic cells. Thus, the diverse anticancer efficacy of PMEDAP treatment among SD/cub lymphomas could be associated with the different phenotypes of individual neoplasias.

• Authors: K Bobková, B Otová, I Marinov, V Mandys, A Panczak, I Votruba, A Holý
• Journal: Anticancer research (Anticancer Res) 2000 Mar-Apr Vol. 20 Issue 2A Pg. 1041-7 ISSN: 0250-7005 [Print] Greece
• PMID: 10810395 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Proto-Oncogene Proteins c-bcl-2
• Tumor Suppressor Protein p53
• 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
• Adenine

Topics

• Adenine (analogs & derivatives, therapeutic use)
• Animals
• Antineoplastic Agents (therapeutic use)
• Apoptosis (drug effects)
• Chromosome Mapping
• Immunohistochemistry
• In Situ Nick-End Labeling
• Karyotyping
• Lymphoma, T-Cell (drug therapy, genetics, pathology)
• Proto-Oncogene Proteins c-bcl-2 (analysis)
• Rats
• Rats, Sprague-Dawley
• Trisomy
• Tumor Suppressor Protein p53 (analysis)